No abstract

Oxidative stress, inflammation, and gut microbiota impairments have been implicated in the development and maintenance of diabetes mellitus. Strategies capable of recovering the community of commensal gut microbiota and controlling diabetes mellitus have increased in recent years. Some lactobacilli strains have an antioxidant and anti-inflammatory system capable of protecting against oxidative stress, inflammation, and diabetes mellitus. Experimental studies and some clinical trials have demonstrated that Limosilactobacillus fermentum strains can beneficially modulate the host antioxidant and anti-inflammatory system, resulting in the amelioration of glucose homeostasis in diabetic conditions. This review presents and discusses the currently available studies on the identification of Limosilactobacillus fermentum strains with anti-diabetic properties, their sources, range of dosage, and the intervention time in experiments with animals and clinical trials. This review strives to serve as a relevant and well-cataloged reference of Limosilactobacillus fermentum strains capable of inducing anti-diabetic effects and promoting health benefits.

Nutritional insults during pregnancy and/or lactation phases increase the risk in offspring for future arterial hypertension. 1-3 Maternal dyslipidaemia is a condition characterized by high levels of total cholesterol (TC), triacylglycerol (TAG), low-density lipoprotein (LDL) and decreased high-density lipoprotein (HDL). 4 Although pregnancy and/or lactation can be recognized as a period of life favourable to increased lipid profile in serum, 5 the dyslipidaemia effects on the offspring are poorly understood. We have developed a maternal diet-induced dyslipidaemic model in rats, characterized by increased serum levels of total cholesterol, LDL-cholesterol, and triacylglycerol, reduced HDL-cholesterol and compromised glucose tolerance and insulin sensitivity in dams.